SG Americas Securities LLC Purchases 4,691 Shares of Novavax, Inc. (NASDAQ:NVAX)

SG Americas Securities LLC boosted its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 0.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,158,967 shares of the biopharmaceutical company’s stock after purchasing an additional 4,691 shares during the period. SG Americas Securities LLC’s holdings in Novavax were worth $9,318,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its holdings in shares of Novavax by 300.4% during the 3rd quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company’s stock valued at $1,226,000 after purchasing an additional 72,894 shares in the last quarter. Neo Ivy Capital Management bought a new position in Novavax in the third quarter valued at approximately $714,000. Geode Capital Management LLC boosted its holdings in shares of Novavax by 9.5% in the third quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock valued at $44,245,000 after buying an additional 304,159 shares during the period. Barclays PLC increased its position in shares of Novavax by 73.9% during the third quarter. Barclays PLC now owns 709,579 shares of the biopharmaceutical company’s stock worth $8,961,000 after acquiring an additional 301,627 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in shares of Novavax by 147.6% during the third quarter. XTX Topco Ltd now owns 63,126 shares of the biopharmaceutical company’s stock worth $797,000 after acquiring an additional 37,631 shares during the period. 53.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director James F. Young sold 4,600 shares of Novavax stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the transaction, the director now owns 57,160 shares in the company, valued at approximately $484,716.80. This trade represents a 7.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the sale, the director now owns 14,770 shares in the company, valued at $133,225.40. This represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock valued at $119,641 in the last quarter. Company insiders own 1.00% of the company’s stock.

Analyst Upgrades and Downgrades

NVAX has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of Novavax in a research note on Tuesday, December 10th. Jefferies Financial Group decreased their price objective on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 16th. Finally, B. Riley reaffirmed a “buy” rating and set a $26.00 price target (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Novavax currently has an average rating of “Hold” and a consensus price target of $17.83.

Novavax Stock Performance

Shares of NASDAQ NVAX opened at $9.55 on Friday. The stock has a 50 day moving average price of $8.65 and a 200 day moving average price of $10.95. The stock has a market capitalization of $1.53 billion, a PE ratio of -4.23 and a beta of 2.07. Novavax, Inc. has a 52 week low of $3.53 and a 52 week high of $23.86.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.07. The company had revenue of $84.51 million during the quarter, compared to analyst estimates of $65.80 million. The company’s quarterly revenue was down 54.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.26) EPS. As a group, research analysts forecast that Novavax, Inc. will post -1.31 EPS for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.